Citius Pharmaceuticals
Income Statement
Last updated:
Income statement is a financial statement that shows how profitable a business was over a given reporting period presenting its revenue, expenses or net income. over the previous period. Total operating expenses were $41,995,681.
Profit Margin
| 2015 | 0 | -2.90M | |
|---|---|---|---|
| 2016 | 0 | -8.29M | |
| 2017 | 0 | -10.38M | |
| 2018 | 0 | -12.53M | |
| 2019 | 0 | -15.57M | |
| 2020 | 0 | -17.67M | |
| 2021 | 0 | -23.12M | |
| 2022 | 0 | -33.64M | |
| 2023 | 0 | -32.54M | |
| 2024 | 0 | -39.42M |
CTXR Income Statement (2015 – 2024)
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|
Revenue | ||||||||||
Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cost of revenue | 0 | 194.31K | 179.67K | 164.86K | 152.36K | 893 | 0 | 2.63K | 0 | 0 |
Gross profit | 0 | -194.31K | -179.67K | -164.86K | -152.36K | -893 | 0 | -2.63K | 0 | 0 |
Operating exp. | ||||||||||
Research and development | 11.90M | 14.81M | 17.65M | 12.24M | 8.81M | 8.59M | 6.56M | 2.93M | 2.93M | 1.79M |
Selling and marketing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total operating expenses | 41.99M | 36.73M | 33.31M | 23.53M | 17.71M | 15.59M | 13.78M | 9.98M | 7.44M | 3.22M |
Operating income | 0 | -36.73M | -33.31M | -23.53M | -17.71M | -15.59M | -13.78M | -9.98M | -7.44M | -3.22M |
Other income (expenses), net | 0 | 4.76M | 251.39K | 477.46K | 162.6K | 36.21K | 1.26M | -398.64K | -838.21K | 327.66K |
Income before tax | -38.84M | -31.96M | -33.06M | -23.05M | -17.54M | -15.56M | -12.53M | -10.38M | -8.29M | -2.90M |
Income tax expense | 576K | 576K | 576K | 70.75K | 125.88K | 16.44K | 1.28M | 850.78K | 8.99K | 4.43K |
Net income | -39.42M | -32.54M | -33.64M | -23.12M | -17.67M | -15.57M | -12.53M | -10.38M | -8.29M | -2.90M |
Earnings per share | ||||||||||
Basic EPS | 0 | -0.23 | -0.23 | -0.21 | -0.45 | -0.77 | -1.17 | -1.89 | -2.29 | -1.37 |
Diluted EPS | 0 | -0.22 | -0.23 | -0.21 | -0.45 | -0.77 | -1.17 | -1.89 | -2.29 | -1.37 |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |